Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

NCT01236391 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: PCI-32765

Sponsor

Pharmacyclics LLC.

Collaborators

[object Object]